biomodal, a life sciences technology company based in Cambridge, England, has launched duet mosaic, a new family of multiomic sequencing workflows for liquid biopsy and translational research. The products enable researchers to extract genetic, epigenetic, and fragmentomic information from a single blood sample. The duet mosaic family includes two workflows optimised for circulating cell-free DNA analysis. They can detect genetic variants, DNA methylation, and fragmentomics from the same DNA molecule without splitting samples across multiple assays. "Researchers and developers are being asked to find a vanishingly small signal in a precious, limited sample," said Robert Osbourne, biomodal's SVP of research and development. The platform uses hairpin-based chemistry and includes integrated software for data analysis. The products are available now for research use in 8, 24, and 96 reaction formats.

Biomodal, an omics-based life sciences technology company, has announced that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 5D multiomics and AVITI sequencing instruments. The integration, validated at the University of Minnesota Genomics Center, aims to enhance sensitivity for cancer, ageing and neurodegenerative disease research. The collaboration combines biomodal's 5-base and 6-base sequencing solutions with Element's sequencing systems, enabling complete methylation detection and delivering actionable insights within a single streamlined process. AVITI users gain access to biomodal's software pipeline, creating an end-to-end workflow for next-generation sequencing. Biomodal's platform-agnostic technology integrates pre-sequencing workflow with post-sequencing informatics to generate genetic and epigenetic data from a single sample in one run.